Alnylam Pharmaceuticals

ALNY

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Alnylam Pharmaceuticals has been a target of short sellers for a while. The current short interest of 4.74% is roughly at the average of the last 12 months (3.66%).